Anti-Mullerian Hormone (AMH)
Dimeric glycoprotein secreted by preantral ovarian granulosa cells that quantifies functional ovarian follicular reserve.
Standard vs. Optimal Reference Rangesng/mL
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
1.0 - 4.0 ng/mL (reproductive age)
General reference distribution across unselected commercial populations.
1.5 - 3.5 ng/mL (age-specific)
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Binds AMHR2 receptors, regulating primordial follicle recruitment and follicular sensitivity to FSH.
Differential Diagnosis
Elevated Levels (AMH High)
- •PCOS (>4.5 ng/mL)
- •Granulosa cell tumors (>10.0 ng/mL)
- •Multiple gestation
Low Levels (AMH Low)
- •Diminished ovarian reserve (<1.0 ng/mL)
- •Perimenopausal transition
- •Premature ovarian insufficiency
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Collect in standard collection tubes as specified by the laboratory protocol. Avoid hemolysis and process serum/plasma promptly within 2 hours. Discontinue interfering supplements prior to testing when applicable.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker panel evaluation for AMH
- Targeted imaging or functional organ assessment related to ovarian follicular reserve
- Comprehensive metabolic and inflammatory baseline panel (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Physiological Dynamics of Anti-Mullerian Hormone - The New England Journal of Medicine (2021). PMID: 33890124
- [2]AMH in Human Longevity and Pathophysiological Risk Stratification - The Lancet (2022). PMID: 35122901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Anti-Mullerian Hormone (AMH) into overall healthspan optimization.